

Ocrelizumab

Cat. No.:	HY-P9960
CAS No.:	637334-45-3
Molecular Weight:	145.82 kDa
Target:	CD20
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) ^{[1][2]} .	
In Vivo	Ocrelizumab (7.5 mg/kg; once daily; 18 days; s.c. or i.v.) inhibits lesions in multiple sclerosis mice by inducing B cell exhaustion through antibody dependent cytotoxicity (ADCC) ^[1] .	
	Ocrelizumab (50 µg; repeat administration on days 7, 14, and 21; i.v.) can reduce B and T cells in the blood, lymph nodes, and spleen of C57BL/6 mice ^[2] .	
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	HuCD20 mice with chronic DTH-TLS lesions ^[1] .
	Dosage:	7.5 mg/kg
	Administration:	Subcutaneous injection (s.c.) or intravenous injection (i.v.); once daily; 18 days; initiated on Days 63, 70 and 75 post lesion induction
	Result:	Reduced the number of CD19+ cells and MS like lesions in the spleen and lymph nodes of mice.
	Animal Model:	C57BL/6 mice ^[2] .
	Dosage:	50 µg
	Administration:	Intravenous injection (i.v.); repeat administration on days 7, 14, and 21
Result:	Reduced the total CD19+ B cells and CD4, CD8 T cells in the blood, spleen, and LN.	

REFERENCES

[1]. Torres JB, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. *Front Immunol.* 2022 Jul 28;13:814064.

[2]. Schubart A, et al. Effect of Subcutaneous vs Intravenous Chronic Treatment with an Anti-CD20 Antibody on B-, T-and Myeloid Lymphocyte Subsets in Blood, Lymph Nodes and Spleen of C57BL/6 Mice (P2. 410)[J]. Neurology, 2018, 90(15_supplement): P2. 410.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA